Vascular access placement in patients with chronic kidney disease Stages 4 and 5 attending an inner city nephrology clinic: a cohort study and survey of providers

Narender Goel1, Caroline Kwon2, Teena P. Zachariah2, Michael Broker2, Vaughn W. Folkert1, Carolyn Bauer1 and Michal L. Melamed1,3*

Abstract

Background: The majority of incident hemodialysis (HD) patients initiate dialysis via catheters. We sought to identify factors associated with initiating hemodialysis with a functioning arterio-venous (AV) access.

Methods: We conducted a retrospective chart review of all adult patients, age >18 years seeing a nephrologist with a diagnosis of CKD stage 4 or 5 during the study period between 06/01/2011 and 08/31/2013 to evaluate the placement of an AV access, initiation of dialysis and we conducted a survey of providers about the process.

Results: The 221 patients (56% female) in the study had median age of 66 years (interquartile range (IQR), 57–75) and were followed for a median of 1.26 years (IQR 0.6–1.68). At study entry, 81% had CKD stage 4 and 19% had CKD stage 5. By the end of study, 48 patients had initiated dialysis. Thirty-four of the patients started dialysis with a catheter (1 failed and 10 maturing AVFs), 9 with an AVF and 5 with an AVG. During the study period, 61 total AV accesses were placed (54 AVF and 7 AVG). A higher urinary protein/creatinine ratio and a lower eGFR were associated with AV access placement and dialysis initiation. A greater number of nephrology visits were associated with AV access creation but not dialysis initiation. Hospitalizations and hospitalizations with an episode of acute kidney injury (AKI) were strongly associated with dialysis initiation (odds ratio (OR) 13.0 (95% confidence interval (CI) 2.3 to 73.3, p-value = 0.004) and OR 6.6 (95% CI 1.9 to 22.8, p-value = 0.003)).

Conclusions: More frequent nephrology clinic visits for patients with a recent hospitalization may improve rates of placement of an AV access. A hospitalization with AKI is strongly associated with the need for dialysis initiation. Nephrologists may not be referring the correct patients to get an AV access surgery.

Keywords: Vascular access, CKD, Acute kidney injury, Hospitalizations, Hemodialysis

Background

Chronic kidney disease (CKD), including end-stage renal disease (ESRD) requiring dialysis or transplantation, affects 16.8% of adults in the United States (US) [1] and is associated with an increased risk of death from cardiovascular disease [2]. Hemodialysis (HD) is the most common form of renal replacement therapy in the US, and thus, particular attention must be given to the placement of a vascular access. Among all available vascular access options, an arterio-venous fistula (AVF) is preferred owing to its longevity and the fewest associated complications. An arterio-venous graft (AVG) is usually placed when a surgeon is unable to place an AVF. Catheters are the least preferred as their use has been shown to be a risk factor for bacteremia and septicemia which correlates with an increased risk of myocardial infarction, stroke, peripheral vascular disease and death [3].

* Correspondence: michal.melamed@einstein.yu.edu
1 Division of Nephrology, Montefiore Medical Center/Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 615, Bronx 10461, NY, USA
2 Department of Epidemiology and Population Health, Montefiore Medical Center/Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 615, Bronx 10461, NY, USA
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
In order to increase the prevalence of AVFs in ESRD patients, the National Kidney Foundation launched the Fistula First Breakthrough Initiative (FFBI) in 2003, which increased AVF use in prevalent ESRD patients from 32% in 2003 to 56% in June 2010. During the same period AVG use has decreased from 40% to 20%, however 82% of patients still initiated HD via a catheter [4].

According to the United States Renal Data System (USRDS), 80% of patients started HD via a catheter in 2013 [5]. Previous studies have shown pre-dialysis education, pre-dialysis nephrology care, more frequent clinical encounters and the presence of insurance as some of the factors associated with the use of an AV access at initiation of dialysis [6–9]. Whether or not a patient has seen a nephrologist prior to starting dialysis may be subject to error depending on the data source [10]. Earlier studies have also shown that only 50% of patients start dialysis within a year of obtaining an AV access, suggesting that nephrologists may not be recognizing which patients will need dialysis [11]. A study of ESRD in the elderly found that among patients with CKD, those who developed acute kidney injury (AKI) had a hazard ratio of developing ESRD almost 5 times the hazard ratio of those who didn’t develop AKI [12]. Thus, potentially one of the biggest risk factors for progression may be difficult to predict.

As there is limited information available about patients with late stage CKD and their specific barriers to AV access placement, we studied all adult patients with CKD stage 4 or 5, to evaluate the timeliness of AV access placement and identify barriers to access placement and factors associated with initiation of dialysis with or without an AV access. We also surveyed nephrologists at our institution to assess their perceptions of the access placement process. We hypothesized that patients seen by a nephrology fellow along with a faculty member would be more likely to have an AV access placed.

**Methods**

**Patients**

We conducted a retrospective chart review of all adult patients, age >18 years seeing a nephrologist with new CKD stage 4 or 5 during the study period between June 1, 2011 and August 31, 2012. Patients were followed via chart review until August 31, 2013. The patients ($n = 31$) who had prior nephrologist follow-up for CKD stage 2 or 3 but were seen during the study period for the first time with a diagnosis of CKD stage 4 or 5 were also included and their day of nephrology visit with CKD stage 4 or 5 diagnosis was considered as the initial study visit. Patients referred to the nephrology clinic at Montefiore Medical Center (MMC) are managed either by faculty nephrologists independently or in conjunction with nephrology fellows. CKD stage 4 was defined as an estimated glomerular filtration rate (eGFR) between 15–29 ml/min/1.73 m$^2$ and CKD stage 5 was defined as an eGFR <15 ml/min/1.73 m$^2$ at study entry. GFR was estimated using the Modification of Diet in Renal Disease (MDRD) formula by the hospital’s laboratory using creatinine measurements that are IDMS-traceable [13].

Patients were excluded from study (Fig. 1) if they refused dialysis ($n = 13$), decided on peritoneal dialysis ($n = 11$) or had an AV access placed before the study period ($n = 17$). These 17 patients had a previous AV access placed due to being post-transplant, transfers from other centers or post-dialysis requiring AKI with an AV access already placed. One additional patient came for a second opinion, did not return to clinic and was not included in this study. Patients were also excluded

![Fig. 1 Study Flow Diagram](image-url)
if they were seeing a nephrologist (at Montefiore) for CKD stage 4 or 5 prior to June 1, 2011.

**Measurements**

Data were extracted using the Clinical Looking Glass (CLG) system (Emerging Health Information Technology, Yonkers, New York), an interactive software application developed at MMC that integrates clinical and administrative datasets [14]. We used CLG to extract demographic data, insurance status, race/ethnicity, body mass index, smoking history, primary language (English, Spanish), co-morbidities as coded by ICD-9 codes (presence or absence of diabetes mellitus, hypertension, congestive heart failure, and peripheral vascular disease) and laboratory data including hemoglobin, serum albumin and creatinine which were measured within 90 days prior to or 15 days after the initial nephrology visit for incident stage 4 and 5 CKD. When multiple values were available, the value closest to the clinic visit was used for analysis.

Electronic medical records were reviewed to get information regarding the number of nephrology visits, eGFR at the time of the visits, CKD etiology, date and eGFR at time of referrals, details of AV access surgery, or if the patient was not referred for access surgery, the reasons for non-referral. We collected data on the number of AV access placed and on the initial vascular access in patients starting HD. We also collected data on hospitalizations and about whether the patients experienced an AKI episode (defined as a creatinine rise $>0.3$ mg/dL) during the hospitalization. A patient was considered lost to follow up if the patient was not seen in any Montefiore clinic in last 6 months of the study period. Data on death was obtained from hospital records and through linkage to the Social Security Administration (SSA) mortality registry. This linkage occurs in a continuous fashion by CLG. Data on dialysis initiation was obtained by 1) review of electronic medical records and 2) search for billings codes for ESRD (585.6) or hemodialysis (39.95) or renal dialysis status (V45.11). Data collection ceased at time of death or dialysis whichever occurred first or at the time the patient was lost to follow-up.

**Nephrologists survey**

We also conducted a web-based anonymous survey of all of the nephrology faculty members (all ABIM certified in Nephrology) and fellows (PGY 4 and 5) using REDCap software [Einstein-Montefiore Institute for Clinical and Translational Research grant support (LILI RR025750)]. Questions and responses in the survey included:

1) In your opinion, what is the main limiting factor in referring patients with CKD stage 4 and 5 to a vascular surgeon?

   Possible answers:
   - Patients’ refusal;
   - patients’ non-compliance;
   - patients not decided about modality of dialysis;
   - nephrologists;
   - insurance status;
   - co-morbidities.

2) In your opinion, what is the main limiting factor in obtaining timely vascular access?

   Possible answers:
   - Nephrologists;
   - vascular surgeon;
   - hospital system and appointments;
   - patients;
   - I am not sure.

For analysis we grouped patients’ refusal and non-compliance as patient factors, nephrologists as nephrologist factor, hospital system and appointment and insurance status as health care system factor, vascular surgeon as vascular surgeon factor. From the chart review, reasons for not getting an AV access placed were categorized as nephrologist reasons, if there was no referral to vascular surgery noted in the chart; patient reasons, if patient refused to undergo AV access surgery or if there was a referral but patient did not make the appointment; hospital system and appointments if patients were waiting for their appointment to be evaluated by vascular surgeon or to undergo AV access surgery or unable to undergo surgery due to lack of insurance.

**Statistical analysis**

We first compared the characteristics of patients seen by faculty alone versus with nephrology fellows using the Mann Whitney test and chi-square tests as appropriate. The primary outcome was AV access placement. We assessed the associations of key variables with vascular surgery referral, AV access placement and initiation of dialysis separately using multivariable logistic regression. Variables of interest included care by a renal fellow, the reasons for non-referral to vascular surgery noted in the chart; patient reasons, if patient refused to undergo AV access surgery or if there was a referral but patient did not make the appointment; hospital system and appointments if patients were waiting for their appointment to be evaluated by vascular surgeon or to undergo AV access surgery or unable to undergo surgery due to lack of insurance.
compared the reasons obtained from the nephrologist survey to the chart review data using Chi Square tests. All statistical analysis was done using STATA version 10.2, Texas, US. All mean values were reported with one standard deviation. Two-sided \( p \)-value <0.05 was considered statistically significant. The study protocol was approved by the institutional review board of the Albert Einstein College of Medicine. The need for informed consent was waived due to the retrospective nature of study involving chart review only. The study was conducted in adherence with the Declaration of Helsinki.

**Results**

The 221 patients (56% female) in the study had mean (± standard deviation) age of 64.8 ± 13.6 years and were followed for a median of 1.26 years (IQR 0.6–1.68 years). Out of the 221 patients, 81% had CKD stage 4 and 19% had CKD stage 5 at study entry. Fourteen percent of patients (\( n = 31 \)) had prior follow-up with CKD stage 2 or 3 but were seen during the study period for the first time with CKD stage 4 (\( n = 30 \)) or stage 5 (\( n = 1 \)). The mean eGFR at study initiation was 20.8 ± 6.4 ml/min/1.73 m\(^2\). As expected, diabetes mellitus (30.8%) and hypertension (25.8%) were the predominant etiologies of CKD. Glomerular diseases, acute kidney injury and multifactorial causes were identified in 4.1%, 4.5% and 4.9% of patients, respectively.

Patients seen by faculty members independently as compared to patients seen in conjunction with fellows were significantly older, predominantly female and less likely to have Medicaid and more likely to have Medicare. The mean hemoglobin and albumin were significantly higher among faculty patients as compared to fellows’ patients, whereas the mean serum creatinine and urinary protein/creatinine ratios were significantly higher among the fellows’ patients (Table 1).

A total of 94 patients (42.5%) were referred to vascular surgery with a mean eGFR at the time of referral of 16.3 ± 5.5 ml/min/1.73 m\(^2\). Access surgery was done in 61 (27.6%) patients (55 AVF and 6 AVG) with mean eGFR of 14.3 ± 6.2 ml/min/1.73 m\(^2\) (Figs. 1 and 2). The median time of referral to the surgeon from the initial nephrology study visit was 28 days (IQR, 0–133) while the median time to see the surgeon from the time of referral was 52 days (IQR, 27–106). The median time to surgery after an appointment with the surgeon was 30 days (IQR, 15–85).

Factors associated with vascular surgery referral were African-American race, a higher number of nephrology clinic visits, lower eGFR and higher urine protein/creatinine ratio (Table 2). Being seen with a renal fellow was not shown to be associated with vascular surgery referral. The only factors shown to be associated with the placement of an AV access were a higher number of nephrology clinic visits, a higher protein/creatinine ratio and lower eGFR at entry to the study. Factors associated with initiation of dialysis were a higher urine protein/creatinine ratio, a lower baseline eGFR and having a hospitalization during follow-up or a hospitalization with an AKI episode during follow-up. Of the 48 patients who started dialysis, 44 of them had a hospitalization with an AKI episode, compared to 4 such hospitalizations in 173 patients who did not start dialysis (\( p \)-value <0.001 for comparison). The predominant reasons for not undergoing an access surgery (\( n = 160 \)) were as follows; 43% of patients were not referred for unknown reasons, 20% of patients had stable eGFR or eGFR >25 ml/min/1.73 m\(^2\), 10% of patients refused and 7% of patients missed their appointment.

Patients who started HD but were not referred for vascular surgery were more likely to have diabetes mellitus, lower hemoglobin, albumin and eGFR levels and higher urinary protein/creatinine ratios compared to patients who did not start HD and not referred. All the patients who started HD and were not referred for vascular surgery had had a hospitalization with an AKI episode compared to only 52% of patients who did not start dialysis and were not referred (\( p <0.001 \)) (Table 3).

By the end of study, 48 patients had started HD with mean eGFR of 9.0 ± 4.9 ml/min/1.73 m\(^2\) (Fig. 1). Of all the patients started on HD, 30 patients (62.5%) saw a nephrologist for less than a year and 17 patients (35.4%) had seen the nephrologist for <6 months. The mean time from the study visit to hemodialysis was similar in patients with initial nephrology visit with CKD stage 5 and CKD stage 4 (0.68 ± 0.5 years and 0.83 ± 0.5 years, \( p = 0.4 \)).

In the survey of 17 out of 30 nephrologists at our institution (57% response rate), patient related factors were thought to be the major limiting factor in vascular surgery referral (88%) and AV access placement (41%). Chart review revealed nephrologists to be the major limiting factors in 51% and 44% cases, respectively (Table 4).

**Discussion**

Our study shows that in patients with diagnosis of CKD stage 4 or 5 at our institution, the majority of patients initiate hemodialysis via catheters. This is especially true in those who saw a nephrologist for less than a year (86.6%) and those with CKD stage 5 at referral (87.5%). Although a much higher proportion of patients with a first nephrology visit with CKD 5 (41%) required dialysis during the study period as compared to CKD 4 (18.3%), the mean time to dialysis initiation was comparable in both groups. Hence, it is important to promptly refer patients for AV access placement who are at high risk of progression to ESRD needing hemodialysis. It is, however, hard for nephrologists to predict which patients will require dialysis [11]. Tangri et al. and Landray et al. have proposed predictive models which may be used to
identify patients for ESRD progression [15, 16]. In our late stage CKD population, hospitalizations and hospitalizations with an AKI episode were strongly associated with the need for dialysis suggesting that nephrologists need to be vigilant with these patients and follow them frequently in clinic.

During the study period, 57% of patients were not referred to vascular surgery and 72% of all patients didn’t undergo AV access placement. During this short follow up with a median number of 4 (IQR 2–8) [mean 5.4 ± 4.1] nephrology visits, it appears difficult to achieve successful placement of an AV access. Hence, late referrals to nephrologists, limited follow-up time, and the nephrologists’ lack of prompt referrals to surgery all together resulted in the predominant use of catheters as an initial vascular access. In a study of vascular access placement, patients with a late nephrology referral had only an 8% likelihood of having AV access creation compared to 39% of patients with early referrals [17]. Even in patients who had an AVF, many were not mature by the time the patients started dialysis and the patients still required a catheter (11 patients started with a catheter but had an AVF which was either maturing (10) or failed (1)). One factor associated with placement of a vascular access was frequent nephrology visits, suggesting that late stage CKD patients may require more frequent clinical visits. We also found that nephrologists perceive patients as the major limiting factor to vascular access placement, however, our chart review showed the nephrologist as a potential barrier. Our results suggest the need to educate nephrologists on the importance of being a leader in obtaining AV access.

| Table 1 Baseline characteristics of study patients. Data presented as either number (percent) or mean (standard deviation) as appropriate |
|-----------------------------------------------|----------------|----------------|----------------|
| Total (221) Faculty (141) Fellow (80)            | p-value       |
| Age [years]                                    | 64.8 (13.6)   | 67.2 (12.9)   | 60.6 (13.7)   | <0.001 |
| Female (%)                                     | 124 (56)      | 91 (64.5)     | 33 (41.2)     | 0.001  |
| Mean BMI [kg/m²]                               | 30.4 (7.0)    | 30.7 (7.1)    | 29.7 (6.9)    | 0.14   |
| Co-morbidities                                 |               |               |               |
| Hypertension (%)                               | 206 (93.2)    | 130 (92.2)    | 76 (95)       | 0.58   |
| Diabetes Mellitus (%)                          | 146 (66)      | 93 (65.9)     | 53 (66.3)     | 0.9    |
| Congestive Heart Failure (%)                   | 96 (43.4)     | 58 (41.1)     | 38 (47.5)     | 0.39   |
| Peripheral Vascular Disease (%)                | 33 (14.9)     | 23 (16.3)     | 10 (12.5)     | 0.55   |
| Race/ Ethnicity                                |               |               |               |
| White (%)                                      | 17 (7.7)      | 14 (9.9)      | 3 (3.7)       | 0.06   |
| African-American (%)                           | 68 (30.8)     | 49 (34.7)     | 19 (23.7)     |        |
| Hispanic                                       | 107 (48.4)    | 63 (44.7)     | 44 (55)       |        |
| Other                                          | 29 (13.1)     | 15 (10.6)     | 14 (17.5)     |        |
| Primary Language                               |               |               |               |
| English (%)                                    | 164 (74.2)    | 108 (76.5)    | 56 (70)       | 0.3    |
| Spanish (%)                                    | 51 (23.2)     | 30 (21.3)     | 21 (26.2)     | 0.4    |
| Insurance                                      |               |               |               |
| Medicaid (%)                                   | 77 (34.8)     | 33 (23.4)     | 44 (55)       | <0.001 |
| Medicare (%)                                   | 70 (31.8)     | 54 (38.3)     | 16 (20)       | 0.006  |
| Never smoker (%)                               | 118 (53.4)    | 76 (53.9)     | 42 (52.5)     | 0.8    |
| Hemoglobin, mean [SD] [gm/dL]                  | 10.7 (1.8)    | 10.9 (1.8)    | 10.3 (1.8)    | 0.04   |
| Albumin, mean [gm/dL]                          | 3.8 (0.6)     | 3.96 (0.6)    | 3.53 (0.7)    | <0.001 |
| Creatinine, mean [mg/dl]                       | 2.88 (1.2)    | 2.7 (1.2)     | 3.18 (1.2)    | 0.005  |
| Renal Clinic visit, mean                       | 5.4 (4.1)     | 5.3 (4.2)     | 5.5 (4.1)     | 0.8    |
| eGFR [ml/min/1.73 m²] at the study entry, median (IQR) | 20.8 (6.4) | 21.3 (6.2) | 19.8 (6.5) | 0.07   |
| Urine albumin/creatinine ratio                  | 0.78 (0.18, 3.73) | 0.51 (0.13, 2.08) | 2.64 (0.44, 5.31) | <0.001 |
| Follow up (years), median (IQR)                | 1.26 (0.6–1.68) | 1.3 (0.75–1.69) | 1.2 (0.4–1.6) | 0.1    |
| Any hospitalization                            | 155 (70.1)    | 89 (63.1)     | 66 (82.5)     | 0.002  |
| Any hospitalization with acute kidney injury episode | 136 (61.5) | 74 (52.5) | 62 (77.5) | <0.001 |
The drive to avoid catheters is due to increased risk of bacteremia, metastatic infections, thrombosis, venous stenosis, need of frequent interventions to maintain their function, increased cost, anemia, cardiovascular events, hospitalizations, and mortality [18]. According to a recent study, creating early AV access may even have an added benefit of decelerating the decline of eGFR in patients with CKD, delaying the onset of ESRD [19]. While it is not clear what the physiologic mechanism of this deceleration is, or if even the deceleration was simply due to more attentive nephrology care for patients that underwent an AV access procedure, the authors of that study speculated that remote ischemic preconditioning caused by the creation of vascular access, may stimulate the release of humoral factors such as adenosine, erythropoietin and nitric oxide that are renal protective [19]. In order to reduce catheter use, planning for an early placement of an AVF is crucial to its success due to the need for maturation of veins and to account for possible failure of maturation. KDOQI guidelines suggested that patients should be referred to vascular surgeon for creation of an AVF when the eGFR is <25 ml/min/1.73 m² [20]. As per DOPPS II data, in countries such as Australia/New Zealand, Germany, and Japan 50−72% of incident ESRD patients started HD with an AVF compared to 16% in the US [21]. This study also showed that countries such as Germany and Japan had much faster referral times to see a surgeon compared to

Table 2 Odds ratio of vascular surgery referral and AV access placement

|                        | Vascular surgery referral (n = 94) | AV access placement (n = 61) | Initiated Dialysis (n = 48) |
|------------------------|----------------------------------|------------------------------|-----------------------------|
|                        | OR ± 95% CI | p-value | OR ± 95% CI | p-value | OR ± 95% CI | p-value |
| Age, per year           | 0.99 ± 0.96 to 1.02 | 0.33 | 0.97 ± 0.94 to 1.00 | 0.06 | 0.98 ± 0.95 to 1.01 | 0.27 |
| African-American Race   | 4.65 ± 1.00 to 21.6 | 0.05 | 1.10 ± 0.27 to 4.46 | 0.89 | 0.72 ± 0.15 to 3.43 | 0.68 |
| Hispanic Ethnicity      | 2.81 ± 0.64 to 12.44 | 0.17 | 0.70 ± 0.18 to 2.76 | 0.61 | 0.51 ± 0.11 to 2.31 | 0.38 |
| Diabetes Mellitus       | 1.29 ± 0.58 to 2.88 | 0.53 | 0.91 ± 0.40 to 2.06 | 0.82 | 1.76 ± 0.66 to 4.71 | 0.26 |
| Log urine protein/creatinine ratio | 1.45 ± 1.13 to 1.86 | 0.003 | 1.36 ± 1.05 to 1.75 | 0.02 | 1.72 ± 1.28 to 2.32 | <0.001 |
| eGFR at the study entry | 0.87 ± 0.82 to 0.93 | <0.001 | 0.89 ± 0.83 to 0.94 | <0.001 | 0.90 ± 0.84 to 0.97 | 0.003 |
| Patient seen with renal fellow | 1.45 ± 0.67 to 3.13 | 0.34 | 1.10 ± 0.25 to 1.49 | 0.82 | 1.35 ± 0.56 to 3.27 | 0.50 |
| Number of nephrology visits | 1.27 ± 1.12 to 1.45 | <0.001 | 1.13 ± 1.01 to 1.25 | 0.03 | 1.02 ± 0.92 to 1.14 | 0.68 |
| Hospitalization during follow-up | 0.97 ± 0.41 to 2.29 | 0.94 | 2.46 ± 0.94 to 6.4 | 0.07 | 13.0 ± 2.3 to 73.3 | 0.004 |
| AKI during hospitalization | 0.78 ± 0.35 to 1.72 | 0.53 | 1.84 ± 0.79 to 4.28 | 0.26 | 6.6 ± 1.89 to 22.8 | 0.003 |

*All models adjusted for age, sex, race/ethnicity, diabetes mellitus, log urinary albumin/creatinine ratio and baseline eGFR. Renal fellow visit, number of renal visits, number of hospitalization, and the presence of AKI during a hospitalization put in individually with the above adjusters. (abbreviations: OR-odds ratio; CI-confidence interval)
Table 3  Characteristics of patients who started dialysis compared to patients who had an AV access placed during the follow-up period

| Characteristic                          | No HD, No referral (n = 114) | Started HD, no referral (n = 13) | No HD, Referred for AV access (n = 59) | Started HD and Referred for AV access (n = 35) | p-value |
|----------------------------------------|-----------------------------|----------------------------------|----------------------------------------|-----------------------------------------------|---------|
| Age, mean (SD)                         | 68.0 (13.3)                 | 60.5 (15.5)                      | 63.3 (13.2)                            | 58.9 (11.7)                                   | 0.002   |
| Female (%)                             | 72 (63)                     | 7 (53)                           | 26 (44)                                | 19 (54)                                       | 0.12    |
| Mean BMI [kg/m²]                       | 31.0 (7.4)                  | 28.7 (9.1)                       | 29.5 (6.0)                             | 30.4 (6.4)                                    | 0.47    |
| Co-morbidities                         |                             |                                  |                                        |                                               |         |
| Hypertension (%)                       | 104 (91)                    | 12 (92)                          | 57 (97)                                | 33 (94)                                       | 0.60    |
| Diabetes Mellitus (%)                  | 68 (60)                     | 10 (77)                          | 38 (64)                                | 30 (86)                                       | 0.03    |
| Congestive Heart Failure (%)           | 45 (39)                     | 9 (69)                           | 24 (41)                                | 18 (51)                                       | 0.15    |
| Peripheral Vascular Disease (%)        | 16 (14)                     | 3 (23)                           | 9 (15)                                 | 5 (14)                                        | 0.86    |
| Race/ Ethnicity                        |                             |                                  |                                        |                                               | 0.15    |
| White N (%)                            | 11 (10)                     | 3 (23)                           | 2 (3)                                  | 1 (3)                                         |         |
| African American (%)                   | 33 (29)                     | 6 (46)                           | 19 (32)                                | 10 (29)                                       |         |
| Hispanic N (%)                         | 52 (45)                     | 4 (31)                           | 30 (51)                                | 21 (60)                                       |         |
| Other N (%)                            | 18 (16)                     | 0                                | 8 (14)                                 | 3 (8)                                         |         |
| Primary Language                       |                             |                                  |                                        |                                               | 0.74    |
| English (%)a                           | 82 (72)                     | 12 (92)                          | 44 (75)                                | 26 (74)                                       |         |
| Spanish (%)a                           | 29 (25)                     | 1 (8)                            | 12 (20)                                | 9 (26)                                        |         |
| Never smoker (%)                       | 67 (59)                     | 4 (31)                           | 30 (50)                                | 17 (49)                                       | 0.45    |
| Hemoglobin, mean (SD) [gm/dL]          | 11.1 (1.8)                  | 9.2 (2.1)                        | 10.5 (1.7)                             | 10.5 (1.9)                                    | 0.001   |
| Albumin, mean [gm/dL]                  | 4.02 (0.55)                 | 3.36 (0.68)                      | 3.77 (0.63)                            | 3.45 (0.59)                                    | <0.001  |
| Creatinine, mean [mg/dL]               | 2.39 (0.80)                 | 3.5 (1.93)                       | 3.04 (1.00)                            | 3.95 (1.46)                                    | <0.001  |
| Hospitalization, N (%)                 | 70 (61)                     | 13 (100)                         | 39 (66)                                | 33 (94)                                       | <0.001  |
| Renal Clinic visit, median (IQR)       | 4 (2 to 7)                  | 2 (1 to 4)                       | 6 (3 to 11)                            | 3 (6 to 9)                                    | <0.001  |
| eGFR [ml/min/1.73 m²] at the study entry, median (IQR) | 26 (21 to 28)             | 20 (16 to 27)                    | 19 (15 to 25)                          | 17 (12 to 20)                                 | <0.001  |
| Hospitalization with AKI episode, N (%) | 59 (52)                     | 13 (100)                         | 33 (56)                                | 31 (89)                                       | <0.001  |
| Urine albumin/creatinine ratio         | 0.27 (0.1 to 0.82)          | 3.83 (1.87 to 5.15)              | 1.48 (0.61 to 5.07)                    | 4.35 (2.38 to 7.87)                           | 0.22    |
| Follow up (years), median (IQR)        | 1.2 (0.6–1.7)               | 0.6 (0.3–1.0)                    | 1.3 (1.1–1.7)                          | 1.3 (0.5–1.5)                                 |         |

Total may not add up to 100% due to missing values

Table 4  Reasons for non-placement of vascular access

| Limiting Factors                  | Vascular Surgery Referral | AV Access placement |
|-----------------------------------|---------------------------|---------------------|
|                                   | Nephrologist Survey       | Observed by chart Review | p-value | Nephrologist Survey | Observed by chart review | p-value |
| Patients                          | 88%a                      | 15%                 | <0.001  | 41%               | 18%                  | 0.01    |
| Nephrologists                     | 6%                        | 51%                 | <0.001  | 6%                | 44%                  | <0.001  |
| Health system problems≠           | 6%                        | 2%                  | 0.19     | 41%               | 11%                  | <0.001  |
| Vascular surgeon                  | NA                        | NA                  | NA       | 0%                | 0%                   | NA      |
| Stable GFR≠                       | NA                        | 27%                 | NA       | 20%               | NA                   | NA      |
| Others                            | NA                        | 5%                  | 12%      | 8%                |                      | 0.5     |

Patient refusal (47%), patient non-compliance (29.4%) and patient not decided about modality of dialysis (11.8%); Health system problems include insurance problems and hospital system and appointment problems including time delay in waiting for surgery or appointment. It was not known to be a barrier at the time of survey hence was not included in survey; “Actual answer: ‘I am not sure’; Abbreviation: NA-Not applicable
the US [21]. Interestingly, an AVF may not always be the best initial access placed in some patients as previously suggested by Kurella Tamura et al. and DeSilva et al. who suggest that an AVG may be better for older patients [22, 23]. This is also suggested by our data as 11 patients started dialysis with a catheter and a “maturing AVF”.

A study of 319 patients by Lopez-Vargas et al [8] recognized that late referral by a nephrologist is an important factor similar to our study. Similarly, the study by Stehman-Breen et al [24] suggested that fewer nephrology visits (<5) prior to initiation to dialysis was associated with decreased odds of permanent vascular access at the initiation of dialysis. Both of these findings are further consolidated by our observation in this study.

Our study provides further insight in to potential barriers involved once a patient is seen by a nephrologist. FFBI suggests educating and providing feedback to nephrologists and vascular surgeons about their center specific data on vascular access placement and the catheter rate in incident patients [25]. Documentation of discussion about renal replacement therapy and plan for AV access placement should be routine [25]. Other suggestions include patient education and developing a hospital system whereby patients with CKD could be identified early and referred timely to nephrologist and/or vascular surgeon [25]. It is also important to identify patients with advanced kidney disease who are at risk of rapid progression to ESRD and need prompt referral to surgeons. From our study, a hospitalization with an AKI episode is one possible way to identify high risk patients. Models predicting patients’ progression to ESRD [15, 16] may be helpful. Appointing a dedicated vascular access nurse has shown to increase the proportions of incident ESRD patients starting HD with AVF from 56% to 75% [26]. Since the implementation of FFBI, which was also later publicized as “catheter last” and “not fistula only”, various quality improvement projects have been successful in improving AV access placement in ESRD patients [27–29].

There are limitations to our study. The chart review was performed retrospectively and thus we didn’t have information on reasons for not referring to a surgeon when not documented in chart. Our definition of an AKI episode, a creatinine rise of 0.3 mg/dL, represents a small decrement in kidney function in patients with advanced CKD which may introduce misclassification of AKI. The survey of nephrologists had a 57% response rate and is subject, like all surveys, to recall bias. We also lacked information on patients who may have initiated HD at other institutions or at an outpatient HD unit and were never seen at our institution thereafter. However, Montefiore Medical Center is the largest provider of care to patients in the Bronx and provides care to over 500,000 of the 1.4 million individuals living in the Bronx. Our ascertainment of deaths was limited by potential time lag from the use of SSA data. Finally, it is a single center study with small numbers. However, there are several strengths to our study. These include a detailed chart review, linkage to mortality data, and prospectively collected data on Nephrologists’ attitudes about vascular access placement.

**Conclusions**

In conclusion, despite the knowledge that starting HD with an AV access is optimal for patient care and survival, we found that late referral to vascular surgeons continue to be a major obstacle in obtaining timely AV access. Earlier referral to nephrologists and surgeons may improve rates of placement of vascular access. In addition, nephrologists may not be referring the correct patients to get an AV access surgery. A hospitalization with AKI is strongly associated with the need for dialysis in patients with CKD stages 4 and 5. However, it is hard for nephrologists to predict AKI. More frequent nephrology clinic visits for patients with a recent hospitalization may improve rates of placement of an AV access, as the number of nephrology visits was the only easily modifiable factor associated with increased likelihood of an AV access placement.

**Abbreviations**

ABIM: American board of internal medicine; AKI: Acute kidney injury; ANOVA: Analysis of variance; AV: Arterio-venous; AVG: Arterio-venous graft; CKD: Chronic kidney disease; CLG: Clinical looking glass; DOPPS: Dialysis outcomes and practice patterns study; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; FFBI: Fistula first breakthrough initiative; HD: Hemodialysis; ICD: International classification of diseases; IQR: Interquartile range; KDOQI: Kidney disease outcomes quality initiative; MDRD: Modification of diet in renal disease; MMC: Montefiore medical center; OR: Odds ratio; SSA: Social security administration; USRDS: United States Renal Data System.

**Acknowledgements**

We would like to thank Dr. Michelle Mokrzycki for reviewing this manuscript and providing her expert comments. This work was presented in abstract form at the National Kidney Foundation Spring Clinical Meeting in Orlando, FL in April 2013.

**Funding**

Dr. Melamed’s time was partially funded by grants from the National Institute of Diabetes, Digestive and Kidney Diseases (DK078774 and DK102174).

**Availability of data and materials**

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

**Authors’ contributions**

NG participated in the conception and design, data acquisition, analyzed and interpreted the data and drafted the manuscript. CK aided in study design, data acquisition and revising the manuscript. TPZ participated in study design, data acquisition and revising the manuscript. MB participated in data acquisition and drafting the manuscript. VF participated in conception and design and data interpretation and revising the manuscript. CB participated in conception and design and data interpretation and revising the manuscript. MLM participated in the conception and design of the study, analysis and interpretation of the data and results, drafting of the manuscript. All the authors read and approved the final manuscript and agree to be accountable for all aspects of the work.
Competing interests
Dr. Vaughn Folkert reports being a member of the Fresenius Medical Advisory Board. None of the other authors declare any conflicts of interest.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study protocol was approved by the institutional review board, an ethics review board, of the Albert Einstein College of Medicine. The need for informed consent was waived due to the retrospective nature of study involving chart review only. The study was conducted in adherence with the Declaration of Helsinki.

Author details
1Division of Nephrology, Montefiore Medical Center/Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 615, Bronx 10461, NY, USA. 2Department of Internal Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 615, Bronx 10461, NY, USA. 3Department of Epidemiology and Population Health, Montefiore Medical Center/Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 615, Bronx 10461, NY, USA.

Received: 17 August 2016 Accepted: 21 December 2016

Published online: 17 January 2017

References
1. Prevalence of Chronic Kidney Disease and Associated Risk Factors — United States, 1999–2004. 2007. (Accessed June 23 2016, at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5608a2.htm).
2. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in adults with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–73.
3. Ishani A, Collins AJ, Heizog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int. 2005;68:311–8.
4. Wish JB. Vascular access for dialysis in the United States: progress, hurdles, controversies, and the future. Semin Dial. 2010;23(6):614–8.
5. United States Renal Data System Report 2011 annual data report. 2011. (Accessed June 23, 2016, at https://www.usrds.org/2011/pdf/v2_ch01_11.pdf).
6. Hurst FP, Abbott KC, Raj O, et al. Arteriovenous fistulas among incident hemodialysis patients in Department of Defense and Veterans Affairs facilities. J Am Soc Nephrol. 2010;21:1571–7.
7. Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis. 2006;48 Suppl 1:S248–S254.
8. Lopez-Vargas PA, Craig JC, Gallagher MP, et al. Barriers to timely arteriovenous fistula creation: a study of providers and patients. Am J Kidney Dis. 2011;57:87–92.
9. Erickson KF, Meil MW, Winkelwaber WC, Chertow GM, Bhattacharya J. Provider visit frequency and vascular access interventions in hemodialysis. Clin J Am Soc Nephrol. 2015;10:269–77.
10. Kim JP, Desai M, Chertow GM, Winkelwaber WC. Validation of reported predialysis nephrologist care of older patients initiating dialysis. J Am Soc Nephrol. 2012;23:1078–85.
11. Bansal N, He C, Murphy DP, Johansen KL, Hsu CY. Timing of preemptive vascular access placement: do we understand the natural history of advanced CKD?: an observational study. BMC Nephrol. 2013;14:115.
12. Ishani A, Xue JL, Himmelstab J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20:223–8.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.
14. Nishimura T, Murakami K, Livingstone MB, Sasaki S, Uenishi K. Adherence to the food-based Japanese dietary guidelines in relation to metabolic risk factors in young Japanese women. Br J Nutr. 2015;114:4645–53.
15. Landray MJ, Emberson JR, Blackwell L, et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis. 2010;56:1082–94.
16. Tangri N, Stevens LA, Giffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305:1553–9.
17. Al-Jaishi AA, Lok CE, Garg AX, Zhang JC, Moist LM. Vascular access creation before hemodialysis initiation and use: a population-based cohort study. Clin J Am Soc Nephrol. 2015;10:418–27.
18. Lok CE, Mokrzycki MH. Prevention and management of catheter-related infection in hemodialysis patients. Kidney Int. 2011;79:587–98.
19. Sumida K, Molnar MZ, Potukuchi PK, et al. Association between vascular access creation and deceleration of estimated glomerular filtration rate decline in late-stage chronic kidney disease patients transitioning to end-stage renal disease. Nephrol Dial Transplant. 2016;30. [Epub ahead of print].
20. Vascular Access Work G. Clinical practice guidelines for vascular access. Am J Kidney Dis. 2006;48 Suppl 1:S248–73.
21. Ether J, Mendelsohn DC, Elder SJ, et al. Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2008;23:3219–26.
22. DeSilva RN, Patibandla BK, Vin Y, et al. Fistula first is not always the best strategy for the elderly. J Am Soc Nephrol. 2013;24:1297–304.
23. Tamura MK, Tan JC, O’Hare AM. Optimizing renal replacement therapy in older adults: a framework for making individualized decisions. Kidney Int. 2012;82:261–9.
24. Stehman-Breen CO, Sherrard DJ, Gillen D, Caps M. Determinants of type and timing of initial permanent hemodialysis vascular access. Kidney Int. 2000;57:639–45.
25. Vassalotti JA, Jennings WC, Beatarding GA, et al. Fistula first breakthrough initiative: targeting catheterlast in fistula first. Semin Dial. 2012;25(5):303–10.
26. Polkinghorne KR, Senerivatne M, Kerr PG. Effect of a vascular access nurse coordinator to reduce central venous catheter use in incident hemodialysis patients: a quality improvement report. Am J Kidney Dis. 2009;53:99–106.
27. Lacson Jr E, Wang W, Devries C, et al. Effects of a nationwide predialysis educational program on modality choice, vascular access, and patient outcomes. Am J Kidney Dis. 2011;58:235–42.
28. Strott KL, Rodgers DJ, Karp SK, Woodruff SD, Wright LD. Increasing the use of arteriovenous fistulas (AVF): a network QI project. Nephrol News Issues. 2004;18:49–53.
29. Wilson SM, Robertson JA, Chen Q, et al. The IMPACT (Incident Management of Patients, Actions Centered on Treatment) program: a quality improvement approach for caring for patients initiating long-term hemodialysis. Am J Kidney Dis. 2012;60:435–43.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit